

Erratum: Molecular Profiling in Neuro-Oncology: Where We Are, Where We're Heading, and How We Ensure Everyone Can Come Along

The Editors of the 2023 *ASCO Educational Book* have authorized correction of the following error that published in the paper by Porter, Wen, and Polley, entitled, "Molecular Profiling in Neuro-Oncology: Where We Are, Where We're Heading, and How We Ensure Everyone Can Come Along" (DOI https://doi.org/10.1200/EDBK_389322).

In the section "Therapy on the Basis of Molecular Profiling," the last paragraph has been updated as follows:

"Trials with targeted therapies against these pathways, for example, abemaciclib for glioblastomas with CDKN2A/B loss, buparlisib **and paxalisib** for tumors with PI3K activation, and

numerous agents against EGFR, have been ineffective. **Paxalisib, a pi3 kinase inhibitor, did not graduate to stage 2 in GBM Agile, although the patients in that trial were not specifically selected for PI3 kinase pathway activation.** Newer agents against EGFR directed at the molecular alterations specific for glioblastomas with good BBB penetration such as BDX1535 and ERAS-801 are in clinical trials."

The authors apologize for the mistake. This article was corrected on June 30, 2023.

DOI: https://doi.org/10.1200/EDBK_389322CX1

